Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
- PMID: 20100965
- PMCID: PMC2834466
- DOI: 10.1200/JCO.2009.22.4725
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
Abstract
PURPOSE Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-mutated breast cancers. Because sporadic triple-negative breast cancer (TNBC) and BRCA1-associated breast cancer share features suggesting common pathogenesis, we conducted a neoadjuvant trial of cisplatin in TNBC and explored specific biomarkers to identify predictors of response. PATIENTS AND METHODS Twenty-eight women with stage II or III breast cancers lacking estrogen and progesterone receptors and HER2/Neu (TNBC) were enrolled and treated with four cycles of cisplatin at 75 mg/m(2) every 21 days. After definitive surgery, patients received standard adjuvant chemotherapy and radiation therapy per their treating physicians. Clinical and pathologic treatment response were assessed, and pretreatment tumor samples were evaluated for selected biomarkers. Results Six (22%) of 28 patients achieved pathologic complete responses, including both patients with BRCA1 germline mutations;18 (64%) patients had a clinical complete or partial response. Fourteen (50%) patients showed good pathologic responses (Miller-Payne score of 3, 4, or 5), 10 had minor responses (Miller-Payne score of 1 or 2), and four (14%) progressed. All TNBCs clustered with reference basal-like tumors by hierarchical clustering. Factors associated with good cisplatin response include young age (P = .001), low BRCA1 mRNA expression (P = .03), BRCA1 promoter methylation (P = .04), p53 nonsense or frameshift mutations (P = .01), and a gene expression signature of E2F3 activation (P = .03). CONCLUSION Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures


Similar articles
-
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.J Natl Cancer Inst Monogr. 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038. J Natl Cancer Inst Monogr. 2011. PMID: 22043054
-
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.J Clin Oncol. 2011 Nov 20;29(33):4373-80. doi: 10.1200/JCO.2010.33.6446. Epub 2011 Oct 17. J Clin Oncol. 2011. PMID: 22010008 Free PMC article.
-
Triple-negative breast cancer: disease entity or title of convenience?Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28. Nat Rev Clin Oncol. 2010. PMID: 20877296 Review.
-
Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.Oncotarget. 2016 Oct 18;7(42):68662-68673. doi: 10.18632/oncotarget.11900. Oncotarget. 2016. PMID: 27626685 Free PMC article.
-
"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.Semin Oncol. 2011 Apr;38(2):254-62. doi: 10.1053/j.seminoncol.2011.01.007. Semin Oncol. 2011. PMID: 21421115 Review.
Cited by
-
DNA Damage Promotes Epithelial Hyperplasia and Fate Mis-specification via Fibroblast Inflammasome Activation.Dev Cell. 2020 Dec 7;55(5):558-573.e6. doi: 10.1016/j.devcel.2020.09.021. Epub 2020 Oct 14. Dev Cell. 2020. PMID: 33058780 Free PMC article.
-
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6. Proc Natl Acad Sci U S A. 2012. PMID: 22869732 Free PMC article.
-
Assessing the role of platinum agents in aggressive breast cancers.Curr Oncol Rep. 2015 Feb;17(2):3. doi: 10.1007/s11912-014-0428-7. Curr Oncol Rep. 2015. PMID: 25665554 Review.
-
Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.Oncol Lett. 2015 Jun;9(6):2787-2790. doi: 10.3892/ol.2015.3123. Epub 2015 Apr 20. Oncol Lett. 2015. PMID: 26137147 Free PMC article.
-
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.Cancers (Basel). 2021 Mar 30;13(7):1586. doi: 10.3390/cancers13071586. Cancers (Basel). 2021. PMID: 33808149 Free PMC article.
References
-
- Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–1281. - PubMed
-
- Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–2334. - PubMed
-
- Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–5685. - PubMed
-
- Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–1485. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous